Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 576 full-time employees. The company went IPO on 2019-10-11. The Company’s pipeline consists of sotrovimab and other product candidates targeting hepatitis B virus (HBV), hepatitis D virus (HDV), influenza A virus, COVID-19, and human immunodeficiency virus (HIV). The company has assembled four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid, through internal development, collaborations and acquisitions. The firm is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218, an HBV-targeting siRNA, is under several Phase II clinical trials. VIR-2218 is also being evaluated in additional Phase II clinical trials with collaborators. VIR-2218 is under Phase II trial in combination with BRII-179, an investigational T cell vaccine, for the treatment of chronic HBV infection.